Skip to main content
Journal cover image

Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF.

Publication ,  Journal Article
Selvaraj, S; Solomon, SD
Published in: JACC. Heart failure
February 2023

Duke Scholars

Published In

JACC. Heart failure

DOI

EISSN

2213-1787

ISSN

2213-1779

Publication Date

February 2023

Volume

11

Issue

2

Start / End Page

261 / 262

Related Subject Headings

  • Ventricular Function, Left
  • Stroke Volume
  • Prognosis
  • Humans
  • Heart Failure
  • Blood Pressure
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Selvaraj, S., & Solomon, S. D. (2023). Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF. JACC. Heart Failure, 11(2), 261–262. https://doi.org/10.1016/j.jchf.2022.12.009
Selvaraj, Senthil, and Scott D. Solomon. “Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF.JACC. Heart Failure 11, no. 2 (February 2023): 261–62. https://doi.org/10.1016/j.jchf.2022.12.009.
Selvaraj, Senthil, and Scott D. Solomon. “Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF.JACC. Heart Failure, vol. 11, no. 2, Feb. 2023, pp. 261–62. Epmc, doi:10.1016/j.jchf.2022.12.009.
Journal cover image

Published In

JACC. Heart failure

DOI

EISSN

2213-1787

ISSN

2213-1779

Publication Date

February 2023

Volume

11

Issue

2

Start / End Page

261 / 262

Related Subject Headings

  • Ventricular Function, Left
  • Stroke Volume
  • Prognosis
  • Humans
  • Heart Failure
  • Blood Pressure
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology